Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia

Andrés Pizzorno; Blandine Padey; Thomas Julien; Sophie Trouillet-Assant; Aurélien Traversier; Elisabeth Errazuriz-Cerda; Julien Fouret; Julia Dubois; Alexandre Gaymard; François-Xavier Lescure; Victoria Dulière; Pauline Brun; Samuel Constant; Julien Poissy; Bruno Lina; Yazdan Yazdanpanah; Olivier Terrier; Manuel Rosa-Calatrava

On top of that, we observed an additional 1.3 log10 reduction in nasal HAE viral titers for the remdesivir-diltiazem combination when compared with remdesivir monotherapy. In all cases, the antiviral effects induced by remdesivir, diltiazem or the remdesivir-diltiazem combination translated into a protection of the nasal but not the bronchial HAE barrier integrity, preventing the 195 drop on TEER values induced by the infection (Fig. 4D, lower panel) . Importantly, remdesivir also showed a strong antiviral effect at 72 hpi (Fig. 4E, upper panel) . This time, the ⁓2 log10 reductions in nasal and bronchial HAE viral titers observed for the remdesivir and remdesivirdiltiazem treatments correlated higher TEER values in both HAE compartments (Fig. 4E The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.31.017889 doi: bioRxiv preprint response of nasal and bronchial HAE. These responses are in line with the viral replication kinetics, and in some cases (6) -but not in others- (31) follow similar trends to what has been described in blood samples from patient cohorts. We expect our results will provide a starting point for future studies aimed at further characterizing the local pathophysiology and immune response to SARS- The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.31.017889 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.31.017889 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.31.017889 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.31.017889 doi: bioRxiv preprint . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.31.017889 doi: bioRxiv preprint